AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05872425
Drug: DingKunDan(GuangYuYuan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment.
Trial: NCT05872425
Drug: Drospirenone and Ethinylestradiol Tablets (Ⅱ)
RxNorm normalized name: drospirenone and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
Trial: NCT05429515
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy protocol will be made by hematologists.
Trial: NCT05351086
Drug: PUR3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
Trial: NCT05658029
Drug: ARINA-1
RxNorm normalized name: ZOSTERA MARINA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590 Dose 1
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590 Dose 2
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The MTD of TLC590
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590 Dose 3 (The SMC-suggested dose)
Trial: NCT06574269
Drug: TLC590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC590
Trial: NCT05844956
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Trial: NCT04374903
Drug: HCQ & AZ vs HCQ+SIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
Trial: NCT05217732
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT05217732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05041543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as eye drops
Trial: NCT04044534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive placebo.
Trial: NCT05883852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
Trial: NCT05655182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
Trial: NCT04452344
Drug: opioid-containing analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocodone/ acetaminophen combination product
Trial: NCT04452344
Drug: two over-the-counter analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of over-the-counter analgesics (ibuprofen/acetaminophen)
Trial: NCT06405204
Drug: Myoinositol
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an enzymatic isoform of inositol and belongs to the vitamin B complex family
Trial: NCT06405204
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
Trial: NCT06405204
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control
Trial: NCT06615557
Drug: Fasedienol Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray delivered 20 minutes before the PSC
Trial: NCT05341089
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05244525
Drug: Bupivacaine with Epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
Trial: NCT05581693
Drug: L04RD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04RD1
Trial: NCT05581693
Drug: L04TD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of L04TD2
Trial: NCT03939273
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: seven day course of placebo tablets and capsules identical in appearance and number to active treatment
Trial: NCT05368805
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
Trial: NCT05582499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT03771612
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
Trial: NCT03771612
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the participants will be randomly assigned to receive a placebo pill twice daily
Trial: NCT05857046
Drug: Melatonin 10 MG
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
Trial: NCT04692493
Drug: non-TNFi-biologic class
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
Trial: NCT06079346
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinic acid, 5-FU, Irinotecan, Oxaliplatin
Trial: NCT04620473
Drug: Capeox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
Trial: NCT05087940
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
Trial: NCT06619236
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05331183
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablets for oral administration.
Trial: NCT06663748
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Trial: NCT05323487
Drug: Bumetanide Injection
RxNorm normalized name: bumetanide Injection
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
Trial: NCT06533384
Drug: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Trial: NCT05031624
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose of normal saline
Trial: NCT01549847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO BID
Trial: NCT05429684
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
Trial: NCT05212532
Drug: EOM613
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peptide nucleic acid (PNA)
Trial: NCT05020483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
Trial: NCT06130384
Drug: Use of bromfenac 0.09% to reduce intravitreal injection pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eyedrop (bromfenac) will be given to the assigned eye.
Trial: NCT06130384
Drug: Use of artificial tears to reduce intravitreal injection pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eyedrop (artificial tears) will be given to the assigned eye.
Trial: NCT04859803
Drug: conventional intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
Trial: NCT05595499
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06001125
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 20 mg PO weekly
Trial: NCT05673135
Drug: Anti-Hypertensive
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For control of the blood pressure
Trial: NCT05437029
Drug: Q-Griffithsin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
Trial: NCT04827537
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (one pill) x two times a day orally, 10 consecutive days
Trial: NCT06671444
Drug: YZJ-1139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, 20 mg tablet
Trial: NCT06673134
Drug: enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exclusive enteral nutrition therapy or Partial enteral nutrition
Trial: NCT06673134
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
Trial: NCT06672263
Drug: TQB3911 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
Trial: NCT06619990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04645797
Drug: APR003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
Trial: NCT06534697
Drug: Naropin, 0.2% Injectable Solution in dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
Trial: NCT06530316
Drug: RET Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RET inhibitors for neoadjuvant treatment
Trial: NCT05634590
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Trial: NCT05634590
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
Trial: NCT04770272
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, day 1 for 4 cycles (12 weeks)
Trial: NCT04651777
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
Trial: NCT04855877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of lactose tablet (placebo)
Trial: NCT04906005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
Trial: NCT02005523
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05457530
Drug: DOR/3TC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
Trial: NCT05457530
Drug: BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
Trial: NCT05386433
Drug: standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-of-care of COVID-19
Trial: NCT06512766
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Trial: NCT06512766
Drug: Retinoids
RxNorm normalized name: Retinoids for cancer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Trial: NCT05035316
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
Trial: NCT05035316
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet: calcium, 1 tablet/day
Trial: NCT05878938
Drug: NNC0365-3769 (Mim8) PPX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
Trial: NCT05379322
Drug: Anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
Trial: NCT05379322
Drug: JAK inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
Trial: NCT06252610
Drug: Radiotracer Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.
Trial: NCT06252610
Drug: Contrast Media, Magnetic Resonance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected.
Trial: NCT06569537
Drug: BLT
RxNorm normalized name: BLT-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Trial: NCT04874038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
Trial: NCT06448780
Drug: Caffeine citrate 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Trial: NCT06448780
Drug: Caffeine citrate 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Trial: NCT06189040
Drug: BNT162b2 30µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular administration of 30µg
Trial: NCT06189040
Drug: BNT162b2 20µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular administration of 20µg
Trial: NCT04964089
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT05211024
Drug: Penicillin G Benzathine
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
Trial: NCT05640934
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
Trial: NCT05640934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.